文献速递中医内科中药与中成药合理使用

中药治疗冠心病的临床证据与可能机制

Traditional Chinese Medicine for Coronary Heart Disease: Clinical Evidence and Possible Mechanisms.
PubMed 文献 · Front Pharmacol · 2019-08-02

系统评价27项高质量随机对照试验(截至2018年6月),评估中药治疗冠心病的疗效与安全性,并汇总动物研究探讨机制。Meta分析显示中药可显著降低心肌梗死、经皮冠状动脉介入和心血管死亡率(P<0.05),改善心功能与临床疗效(P<0.05),患者耐受良好;机制可能涉及抗炎、抗氧化、抗凋亡、改善循环及调节能量代谢等多条信号通路。

要点

  • 中药可降低冠心病患者心肌梗死、PCI和心血管死亡率(P<0.05)
  • 中药可改善收缩功能、ST段压低和临床疗效(P<0.05)
  • 中药耐受性良好,机制涉及抗炎、抗氧化、抗凋亡等

核心结论

  • 中药对冠心病有益且总体安全,可降低心肌梗死、PCI和心血管死亡率并改善心功能与临床疗效。

研究设计与样本

  • 系统评价基于高质量随机对照试验(RCT)和动物研究,共纳入27项合格研究,检索8个数据库(截至2018年6月)。
  • 采用Cochrane协作网推荐的7条目清单评估方法学质量,研究质量评分为4至7分。

主要发现

  • Meta分析显示中药显著降低心肌梗死发生率、经皮冠状动脉介入(PCI)和心血管死亡率(P<0.05)。
  • 中药显著增加心脏收缩功能、改善ST段压低和临床疗效(P<0.05)。
  • 11项研究报告不良事件,中药在冠心病患者中耐受良好。
  • 动物研究提示中药通过抗炎、抗氧化、抗凋亡、改善循环和调节能量代谢等多条信号通路发挥心脏保护作用。

关键数值与推荐

  • 中药降低心肌梗死、PCI和心血管死亡率的效应均P<0.05。
  • 中药改善收缩功能、ST段压低和临床疗效的效应均P<0.05。
  • 研究质量评分范围为4至7分(7条目Cochrane清单)。

临床怎么用

  • 在冠心病患者中可考虑联合中药治疗以降低心肌梗死、PCI和心血管死亡风险并改善心功能。
  • 使用中药时需关注不良事件,现有证据显示患者耐受性良好。

局限性

  • 仅纳入截至2018年6月的研究,研究质量评分4至7分,方法学质量存在差异。
  • 机制总结基于动物研究,向临床转化需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronary heart disease (CHD) remains a major cause of mortality with a huge economic burden on healthcare worldwide. Here, we conducted a systematic review to investigate the efficacy and safety of Chinese herbal medicine (CHM) for CHD based on high-quality randomized controlled trials (RCTs) and summarized its possible mechanisms according to animal-based researches. 27 eligible studies were identified in eight database searches from inception to June 2018. The methodological quality was assessed using seven-item checklist recommended by Cochrane Collaboration. All the data were analyzed using Rev-Man 5.3 software. As a result, the score of study quality ranged from 4 to 7 points. Meta-analyses showed CHM can significantly reduce the incidence of myocardial infarction and percutaneous coronary intervention, and cardiovascular mortality (P < 0.05), and increase systolic function of heart, the ST-segment depression, and clinical efficacy (P < 0.05). Adverse events were reported in 11 studies, and CHMs were well tolerated in patients with CHD. In addition, CHM exerted cardioprotection for CHD, possibly altering multiple signal pathways through anti-inflammatory, anti-oxidation, anti-apoptosis, improving the circulation, and regulating energy metabolism. In conclusion, the evidence available from present study revealed that CHMs are beneficial for CHD and are generally safe.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang KJ, Zheng Q, Zhu PC, et al. Traditional Chinese Medicine for Coronary Heart Disease: Clinical Evidence and Possible Mechanisms. Front Pharmacol. 2019. PMID: 31427964. doi:10.3389/fphar.2019.00844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。